Try a new search

Format these results:

Searched for:



Total Results:


Commentary: Postrepair mitral stenosis: A pyrrhic victory [Editorial]

Chen, Stacey; Grossi, Eugene A
PMID: 33526275
ISSN: 1097-685x
CID: 4776012

Commentary: New onset atrial fibrillation: Not just a nuisance [Editorial]

Chen, Stacey; Grossi, Eugene A
PMID: 34024618
ISSN: 1097-685x
CID: 4887442

Commentary: Just shy of a bullseye! [Editorial]

James, Les; Grossi, Eugene A
PMID: 34953567
ISSN: 1097-685x
CID: 5107912

Commentary: Reap what you sew: Excellent advice for a conservative algorithm for robotic mitral surgery [Editorial]

Nafday, Heidi B; Grossi, Eugene A
PMID: 33526276
ISSN: 1097-685x
CID: 4776022

Robotic mitral valve repair with complete excision of mitral annular calcification [Editorial]

Naito, Noritsugu; Grossi, Eugene A; Nafday, Heidi B; Loulmet, Didier F
PMID: 36237590
ISSN: 2225-319x
CID: 5361162

Commentary: Aortic valve endocarditis: Flexibility is the operative principle in the art of war [Editorial]

Nafday, Heidi B; Grossi, Eugene A
PMID: 33070944
ISSN: 1097-685x
CID: 4641922

Incidence, Management, and Outcomes of Patients With COVID-19 and Pneumothorax

Geraci, Travis C; Williams, David; Chen, Stacey; Grossi, Eugene; Chang, Stephanie; Cerfolio, Robert J; Bizekis, Costas; Zervos, Michael
BACKGROUND:Our objective was to report the incidence, management, and outcomes of patients who developed a secondary pneumothorax while admitted for coronavirus disease 2019 (COVID-19). METHODS:A single-institution, retrospective review of patients admitted for COVID-19 with a diagnosis of pneumothorax between March 1, 2020, and April 30, 2020, was performed. The primary assessment was the incidence of pneumothorax. Secondarily, we analyzed clinical outcomes of patients requiring tube thoracostomy, including those requiring operative intervention. RESULTS:From March 1, 2020, to April 30, 2020, 118 of 1595 patients (7.4%) admitted for COVID-19 developed a pneumothorax. Of these, 92 (5.8%) required tube thoracostomy drainage for a median of 12 days (interquartile range 5-25 days). The majority of patients (95 of 118, 80.5%) were on mechanical ventilation at the time of pneumothorax, 17 (14.4%) were iatrogenic, and 25 patients (21.2%) demonstrated tension physiology. Placement of a large-bore chest tube (20 F or greater) was associated with fewer tube-related complications than a small-bore tube (14 F or less) (14 vs 26 events, P = .011). Six patients with pneumothorax (5.1%) required operative management for a persistent alveolar-pleural fistula. In patients with pneumothorax, median hospital stay was 36 days (interquartile range 20-63 days) and in-hospital mortality was significantly higher than for those without pneumothorax (58% vs 13%, P < .001). CONCLUSIONS:The incidence of secondary pneumothorax in patients admitted for COVID-19 is 7.4%, most commonly occurring in patients requiring mechanical ventilation, and is associated with an in-hospital mortality rate of 58%. Placement of large-bore chest tubes is associated with fewer complications than small-bore tubes.
PMID: 34481799
ISSN: 1552-6259
CID: 5067052

Multiple aortic valve papillary fibroelastomas: A case series of totally endoscopic resections [Case Report]

James, Les; Ostro, Natalie; Narula, Navneet; Loulmet, Didier F; Grossi, Eugene A
PMID: 35967225
ISSN: 2666-2507
CID: 5299722

One-Year Outcomes With Venovenous Extracorporeal Membrane Oxygenation Support for Severe COVID-19

Smith, Deane E; Chang, Stephanie H; Geraci, Travis C; James, Les; Kon, Zachary N; Carillo, Julius A; Alimi, Marjan; Williams, David; Scheinerman, Joshua A; Cerfolio, Robert J; Grossi, Eugene A; Moazami, Nader; Galloway, Aubrey C
BACKGROUND:Severe coronavirus disease 2019 (COVID-19) can cause acute respiratory failure requiring mechanical ventilation. Venovenous (VV) extracorporeal membrane oxygenation (ECMO) has been used in patients in whom conventional mechanical ventilatory support has failed. To date, published data have focused on survival from ECMO and survival to discharge. In addition to survival to discharge, this study reports 1-year follow-up data for patients who were successfully discharged from the hospital. METHODS:A single-institution, retrospective review of all patients with severe COVID-19 who were cannulated for VV-ECMO between March 10, 2020 and May 1, 2020 was performed. A multidisciplinary ECMO team evaluated, selected, and managed patients with ECMO support. The primary outcome of this study was survival to discharge. Available 1-year follow-up data are also reported. RESULTS:A total of 30 patients were supported with VV-ECMO, and 27 patients (90%) survived to discharge. All patients were discharged home or to acute rehabilitation on room air, except for 1 patient (3.7%), who required supplemental oxygen therapy. At a median follow-up of 10.8 months (interquartile range [IQR], 8.9-14.4 months) since ECMO cannulation, survival was 86.7%, including 1 patient who underwent lung transplantation. Of the patients discharged from the hospital, 44.4% (12/27) had pulmonary function testing, with a median percent predicted forced expiratory volume of 100% (IQR, 91%-110%). For survivors, a 6-minute walk test was performed in 59.3% (16/27), with a median value of 350 m (IQR, 286-379 m). CONCLUSIONS:A well-defined patient selection and management strategy of VV-ECMO support in patients with severe COVID-19 resulted in exceptional survival to discharge that was sustained at 1-year after ECMO cannulation.
PMID: 35282865
ISSN: 1552-6259
CID: 5183722

Commentary: "Kicking the can down the road"

James, Les; Grossi, Eugene A
PMID: 35398925
ISSN: 1540-8191
CID: 5218872